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Suppression of experimental crescentic glomerulonephritis by
interleukin-10 gene transfer.
Background. Investigated were effects of overexpression of
interleukin-10 (IL-10) on the outcome and progression of cres-
centic glomerulonephritis in Wistar-Kyoto (WKY) rats.
Methods. Rats were singly or simultaneously injected with
antiglomerular basement membrane (a-GBM) antibody and
adenoviral vector encoding rat IL-10 (Ad-rIL-10) or LacZ (Ad-
LacZ) (3 × 1010 pfu/rat) intravenously, and were sacrificed at
day 7. Their kidneys and other organs were isolated and exam-
ined by histology and immunohistochemistry. The In vivo ex-
pression of IL-10 mRNA in the liver of Ad-rIL-10–injected rats
was confirmed by both reverse transcription-polymerase chain
reaction (RT-PCR) and ribonuclease protection assay analy-
sis and its translated protein was measured in the serum by
enzyme-linked immunosorbent assay (ELISA).
Results. The exogenous IL-10 mRNA was strongly expressed
in the liver in a dose-dependent manner and was intense at
days 4 and 7 but was less intense at day 14. Ad-rIL-10 treat-
ment significantly reduced the incidence of glomerular cres-
cent formation from 67% ± 1.9% in a-GBM antibody–treated
group or 69.8%±1.9% in a-GBM antibody+Ad-LacZ–treated
group to 21.6% ± 1.8% (P < 0.001), the glomerular infiltration
of macrophages from 35.7 ± 6.3 cell s/gcs (a-GBM antibody)
or 37.6 ± 8.6 cells/gcs (both a-GBM antibody + Ad-LacZ) to
17.9 ± 5.5 cells/gcs (P < 0.001), that of major histocompati-
bility complex (MHC) class II–positive cells from 14.4 ± 5.3
cells/gcs (a-GBM antibody) or 15 ± 4.6 cells/gcs (a-GBM anti-
body + Ad-LacZ) to 5.7 ± 2.3 cells/gcs (P < 0.0001) at day 7,
the glomerular and immune tissue expression of IL-1b mRNA,
as well as the proteinuria from 159.0 ± 22.7 mg/24 hours (a-
GBM antibody) or 166 ± 28 mg/24 hours (a-GBM antibody
+ Ad-LacZ) to 42.2 ± 35.2 mg/24 hours (P < 0.01) at day
7. The serum creatinine and blood urea nitrogen levels were
also reduced from 2.8 ± 0.1 mg/dL (a-GBM antibody) or 2.8 ±
0.1 mg/dL (a-GBM antibody + Ad-LacZ) to 1.0 ± 0.1 mg/dL
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(P < 0.001) and from 63.2 ± 8.9 mg/dL (a-GBM antibody) or
61.3 ± 5.2 mg/dL (a-GBM antibody + Ad-LacZ) to 27.0 ±
4.5 mg/dL (P < 0.001), respectively. However, the glomerular
accumulation of CD8+ T cells was unaffected: 5.4 ± 1.1 cells/gcs
(a-GBM antibody + Ad-rIL-10), 5.9 ± 1.5 cells/gcs (a-GBM an-
tibody), and 5.8 ± 1.1 cells/gcs (a-GBM antibody + Ad-LacZ)
(P = NS).
Conclusion. IL-10 gene transfer significantly attenuated the
glomerular lesions and injury in the anti-GBM crescentic
glomerulonephritis of WKY rats.
Crescentic glomerulonephritis induced by an intra-
venous administration of antirat glomerular basement
membrane (a-GBM) antibody in Wistar-Kyoto (WKY)
rats is a model of glomerular diseases that rapidly pro-
gresses to renal failure [1]. This experimental model
is characterized by numerous accumulation of mono-
cytes/macrophages (Mo/Mφ) in the glomeruli associated
with crescent formation, massive proteinuria and pro-
gression to irreversible renal failure. Although CD8+
T cells is a minor population in the glomerular infiltrates,
their crucial role in the induction of this model has been
demonstrated since the glomerulonephritis was almost
completely suppressed in CD8+ T-cell–depleted animals
[2–5]. Proinflammatory cytokines and molecules released
from these infiltrates are suggested to play central roles in
the induction and progression of this glomerulonephritis
[6, 7].
A series of studies have explored an involvement of
cellular immunity, especially T-helper 1–mediated im-
mune responses in the pathogenesis and progression
of an accelerated a-GBM glomerulonephritis model in
mice [8–10]. The model was demonstrated to feature a
T-helper 1–directed delayed type hypersensitivity re-
sponse. Administration of recombinant T-helper 2 cy-
tokine(s), interleukin-10 (IL-10), and IL-4 was shown
to prevent development of the glomerulonephritis and
attenuate its progression to renal insufficiency. The re-
sults were concordant with the evidence that T-helper
1 response was suppressed by IL-10 by blocking the
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production and function of T-helper 1 cytokines [11].
IL-10 inhibits T-helper 1–dominated immune response
in vivo, and basically it has been used in the treatment
of experimental autoimmune and inflammatory disor-
ders such as contact hypersensitivity, rheumatoid arthri-
tis, and inflammatory bowel disease [12–14]. Moreover,
now a body of evidence supports that IL-10 can also in-
hibit many functions and activities of Mo and Mφ and
their antigen presentation capacities [15–18]. However,
when an administration of IL-10 recombinant protein was
tested for preventative and/or therapeutic effects on an
accelerated a-GBM crescentic glomerulonephritis in rats,
the results were not successful [19]. No beneficial effects
of the administration were observed in this study, sug-
gesting inconsistent and even controversial consequences
from one model to another [19, 20]. A possible reason for
the differential effect may be due to inconsistence of the
levels in the circulation when the recombinant IL-10 was
given intravenously once a day.
Gene delivery system has recently been proposed to
have potential therapeutic applications in renal diseases
since gene expression is maintained in certain periods
up to months [21–23]. Gene transfer using adenovirus
vectors encoding interest genes has been succeeded in
therapeutic effects on several experimental renal injury
models [24–26]. As an alternative trial to IL-10 recombi-
nant protein and its limitations, this study was aimed to
determine the effect(s) of IL-10 gene transfer that is me-
diated by adenoviral vector on the outcome and feature
of a-GBM crescentic glomerulonephritis in WKY rats.
METHODS
Construction of adenoviral vectors
Adenoviral vectors encoding rat IL-10 cDNA se-
quences (Ad-rIL-10) or Escherichia coli LacZ gene
(Ad-LacZ) are provided by the GVPN (www.vectors.
nantes.inserm.fr/). Their construction and propagation
were previously described [27, 28]. Briefly, they are con-
structed by homologous recombination in 293 human
cells of DNA from Add1324 (E1- and E3-deleted Ad5
adenovirus) and rat IL-10 cDNA sequences or E. coli
LacZ gene under the transcriptional control of the hu-
man elongation factor 1a (EF1a) promoter. The resulting
constructed vectors contained (from 5′ to 3′) Ad5 sequent
1–392, EF1a promoter, either rat IL-10 cDNA sequences
or E. coli LacZ gene, SV40 polyadenylation sequences
and the 3′ portion of the Add1324 genome.
Induction of a-GBM glomerulonephritis
and experimental schedule
All animals used in these experiments were inbred fe-
male WKY rats, aged 12 to 16 weeks, and weighing 150 to
220 g. The animals were kept in the metabolic cages for
24-hour urine collection and at day 0 they were divided
into four groups of five rats each. The first group served
as a normal control, and the second group received a-
GBM antibody in a dose of 25 lL (containing 325 lg of
rabbit IgG) per 100 g body weight as described previ-
ously [2]. Simultaneously and in different tail veins, rats
of the third group were intravenously injected with the a-
GBM antibody and Ad-LacZ (3 × 1010 pfu/rat), and those
of the fourth group were treated with the a-GBM anti-
body and Ad-rIL-10 (3 × 1010 pfu/rat). The urine samples
were collected at days 0, 2, 4, and 7 by housing the rats in
metabolic cages. The animals were sacrificed at day 7 and
their kidneys, spleens, lymph nodes, and serum samples
were isolated.
Two preliminary experiments were conducted prior to
this study to examine effects of the gene transfer on the
development and progression of the disease. The first one
was aimed to show the relation ship between the injected
dose of Ad-rIL-10 and the expression level of its derived
IL-10 mRNA 7 days after the injection. Three doses of
Ad-rIL-10 were tested (1 × 1010, 3 × 1010, and 10 × 1010
pfu/rat, respectively) in this experiment. The second one
was performed to examine the time course of Ad-rIL-
10 expression efficacy. The Ad-rIL-10 in a dose of 10 ×
1010 pfu/rat was given intravenously and the animals were
sacrificed after 4, 7, and 14 days.
Detection of Ad-rIL-10 expression by reverse
transcription-polymerase chain reaction (RT-PCR)
Total RNA samples were isolated from livers and
other organs of normal control animals or those treated
with a-GBM antibody alone, a-GBM antibody plus Ad-
LacZ, or a-GBM antibody plus Ad-rIL-10. These iso-
lated RNAs were reverse transcribed to cDNAs, and
then these cDNA products were denaturated and used
for two separate sets of PCR amplifications. The first
PCR was performed to amplify the 3′ portion of ade-
noviral vector nucleotide sequences. For this aim, the
sequences of sense and antisense primers were used cor-
responding to the adenovirus type 5 nucleotide positions
4565–4584 bp (5-′GACGCCCTTGTGACCTCCAA-3′)
and 5072–5053 (5′-CGGCGAGCGCCTTCTGGCGG-
3′), respectively. The PCR cycle conditions were de-
naturation at 94◦C for 60 seconds and annealing at
68◦C for 5 minutes through 35 cycles followed by a
terminal extension at 72◦C for 7 minutes [29]. The
second set of RT-PCR amplification was aimed to amplify
the IL-10 mRNA that is derived from Ad-rIL-10 gene
transferred by differentiation from the endogenous rat
IL-10. Accordingly, the DNA sequences corresponded
to the first exon of the EF1a promoter (5′-GGTTT
GCCGCCAGAACACAG-3′) was selected as a sense
primer and that sequence corresponded to the inserted
rat IL-10 (5′-CCTTGCTTTTATTCTCAGAGG-3′) as an
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antisense primer. The PCR cycle conditions were 94◦C
for 30 seconds, 60◦C for 30 seconds, and 72◦C for 30 sec-
onds through 35 cycles [27]. These PCR products were
subcloned and the DNA sequences were verified by an
automated DNA sequencer.
Detection of Ad-rIL10 expression by ribonuclease
protection assay
Fifteen micrograms of RNA samples isolated from liv-
ers and other organs of normal, a-GBM antibody alone,
a-GBM antibody + Ad-LacZ, and a-GBM antibody +
Ad-rIL-10–treated rats were hybridized with a mixture of
32P-labeled IL-10 and glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) antisense RNA probes (each was
1 × 105 cpm) for overnight at 45◦C. Unhybridized RNA
probes were digested with RNase T1 (Life Technolo-
gies, Gaithersburg, MD, USA) and RNase A (Boehringer
Mannheim, Tokyo, Japan) for 1 hour at 30◦C. The RNases
were then digested with proteinase K (Promega, Madi-
son, WI, USA) for 30 minutes at 37◦C. After phe-
nol/chloroform extraction and sodium acetate/ethanol
precipitation, the hybridized RNA probes were denat-
urated at 85◦C for 5 minutes and electrophoresed on a
6% polyacrylamide gel, then the dried gels were exposed
to x-ray films.
Detection of IL-10 protein level in the serum
by enzyme-linked immunosorbent assay (ELISA)
The serum concentrations of rIL-10 protein of nor-
mal, a-GBM antibody, a-GBM antibody + Ad-LacZ, and
a-GBM antibody + Ad-rIL-10–treated animals were de-
termined at day 7 by using an ELISA technique according
to the manufacturer’s instruction (Rat IL-10 Immunoas-
say Kit, Quantikine M; R&D Systems, Inc., Minneapolis,
MN, USA). The minimum detectable dose of rat IL-10
was less than 10 pg/mL.
Renal tissue preparation and disease evaluation
At the times of sacrifice, each kidney was divided into
three parts. The first part was fixed in methyl carnoy fix-
ative and embedded in paraffin. The second part was
quick-frozen in n-hexane at −70◦C. The rest of the kid-
ney was used for isolation of RNA from glomeruli and
cortices. In this study, the renal damage was assessed by
five parameters.
Examination of kidney histology. Paraffin-embedded
kidney sections were stained with periodic acid-Schiff
(PAS) reagent and the number of crescentic glomeruli
per 100 glomeruli of each rat was counted and expressed
as a percentage.
Immunohistochemical examination of glomerular infil-
trates. The paraffin embedded sections (5 lm thickness)
were stained with endothelin-1 (ED-1) monoclonal an-
tibody against Mo/Mφ (Dainippon Seiyaku Co., Tokyo,
Japan) and with OX8 monoclonal antibody against CD8+
cells (PHLS Center for Applied Microbiology and Re-
search, Wiltshire, UK), while the cryostat frozen sec-
tions (4 lm thickness) were stained with OX6 mono-
clonal antibody against major histocompatibility complex
(MHC) class II–positive cells (Serotec, Oxford, UK). A
minimum of 50 equatorially sectioned glomeruli were as-
sessed per animal and the results were expressed as cells
per glomerular cross section (c/gcs).
Detection of IL-1b mRNA expression in glomeruli and
immune tissues by ribonuclease protection assay. The
preparation of 32P-labeled IL-1b RNA probe and the de-
tection of its mRNA expression have been described pre-
viously [5]. Ten micrograms of glomerular, spleen, and
lymph node RNA samples were hybridized with 1 × 105
cpm of 32P-labeled IL-1b antisense RNA probe overnight
at 45◦C.
Urinary protein excretion. Urine samples were col-
lected at days 0, 2, 4, and 7. The amount of protein
excreted in the urine samples was determined by using
protein assay kit (Nippon Bio-Rad Laboratories, Tokyo,
Japan).
Serum creatinine and blood urea nitrogen (BUN) levels.
Serum samples were collected at day 7 and kept at −20◦C
until the analysis. The serum creatinine and BUN concen-
trations (mg/dL) were evaluated respectively by using
the modified Jaffe and the urease-indophenol methods
(Wako Pure Chemical Industries, Ltd., Osaka, Japan).
Statistical analysis
Data are expressed as mean ± SD. Stastistical evalua-
tion was done by Mann-Whitney test and P value < 0.05
was considered to be significant.
RESULTS
Expression of transferred IL-10 gene
Two sets of RT- PCR amplifications were carried out
in this study. The first one was amplified the 3′ portion
of adenoviral vector nucleotide sequences and the cor-
responding band (488 bp) was intensely detected in liv-
ers ofAd-rIL-10 or Ad-LacZ–treated animals but not of
other animals (Fig. 1A). The second set of the RT-PCR
amplification aimed to amplify the IL-10 mRNA that
should expressed from the injected Ad-rIL-10 and not
from endogenous source. As shown in Figure 1B, the am-
plified band (440 bp) of this exogenous IL-10 mRNA was
clearly detected in the livers of Ad-rIL-10–treated ani-
mals but not of Ad-LacZ–treated or control ones.
By ribonuclease protection assay analysis, a paral-
lel correlation between the injected dose of Ad-rIL-10
(1 × 1010, 3 × 1010, and 10 × 1010 pfu/rat, respectively)
and the expression level of its derived IL-10 mRNA
El-Shemi et al: Suppression of crescentic glomerulonephritis by IL–10 gene transfer 1283
Ma
rke
r
Ad-rIL-10 Ad-LacZ
488 bp
1 2 3 4 5 6 7 8 9 10
Co
ntr
ol
Ma
rke
r Ad-rIL-10 Ad-LacZ
1 2 3 4 5 6 7 8
Co
ntr
ol
440 bp
A B
Fig. 1. Detection of adenoviral vector encoding rat interleukin-10 (Ad-rIL-10) gene expression by reverse transcription-polymerase chain reaction
(RT-PCR). (A) PCR amplification of the 3′ end of adenoviral vector nucleotide sequences shows an amplified band (488 bp) in livers isolated from
Ad-rIL-10 (3 × 1010 pfu/rat)–treated (lanes 1 to 5) or Ad-LacZ (3 × 1010 pfu/rat)–treated animals (lanes 6 to 9) but not in normal controls (lane 10).
(B) Exogenous IL-10 mRNA that is expressed from Ad-rIL-10 (3 × 1010 pfu/rat) administration and not from endogenous sources was detected
by PCR amplification using specific primers as mentioned in the Methods section. The amplified PCR band (440 bp) is detected only in livers of
animals who received Ad-rIL-10 (lanes 1 to 4) but not those who treated with Ad-LacZ (lanes 5 to 7) or normal controls (lane 8).
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Fig. 2. Detection of adenoviral vector en-
coding rat interleukin-10 (Ad-rIL-10) expres-
sion in liver by ribonuclease protection assay
(RPA). (A) A representative RNase protec-
tion assay showing a parallel correlation be-
tween the injected dose of Ad-rIL-10 (1 ×
1010, 3 × 1010, and 10 × 1010 pfu/rat) and the
level of its expressed IL-10 mRNA (lanes 1,
2, and 3, respectively). Animals of lane 4 are
those injected with anti-glomerular basement
membrane (a-GBM) antibody + Ad-LacZ
(3 × 1010 pfu/rat) and those in lane 5 are
normal controls. (B) A representative set of
RNase protection assay showing the relation-
ship between the time course and the express-
ing efficacy of Ad-rIL-10 (10 × 1010 pfu/rat).
This exogenous IL-10 mRNA was strongly ex-
pressed in the liver at days 4 and 7 but was less
intense at day 14 (lanes 3, 4, and 5, respec-
tively). Lane 1 is normal control and lane 2
is a-GBM antibody + Ad-LacZ–treated ani-
mals. GAPDH is glyceraldehyde-3-phosphate
dehydrogenase.
was confirmed in the liver (Fig. 2A). In addition, the
time-dependent expression efficacy of the Ad-rIL-10 for
its mediated IL-10 mRNA was also examined and the
peaked levels were observed at days 4 and 7 and then
decreased at day 14 (Fig. 2B).
At day 7 of the experiment, the serum concentration of
IL-10 protein was 48.0 ± 26.9 pg/mL in a-GBM antibody
+ Ad-rIL-10 (3 × 1010 pfu/rat)–treated rats and the level
was less than 10 pg/mL in normal, a-GBM antibody– and
a-GBM + Ad-LacZ (3 × 1010 pfu/rat)–treated animals
(Fig. 3).
Effect of Ad-rIL-10 gene expression on the outcome and
progression of a-GBM crescentic glomerulonephritis in
WKY rats
Histology and immunohistochemistry. The glomeruli
were enlarged with hypercellurality and with marked
accumulation of mononuclear cells and deposition of
proteineous materials 7 days after the a-GBM antibody
administration. Crescentic formation was frequently ob-
served in these diseased glomeruli (67% ± 1.9%).
The transfer of Ad-rIL-10 (3 × 1010 pfu), but not
Ad-LacZ, to the a-GBM antibody–injected rats reduced
these glomerular lesions markedly (Fig. 4). The number
of crescentic glomeruli was also decreased significantly
to 21.6% ± 1.8% in the Ad-rIL-10–transferred animals
at day 7 (P < 0.001 vs. 67% ± 1.9% in a-GBM antibody–
treated group). No effects on the crescent formation were
observed in the Ad-LacZ–transferred animals (69.8% ±
1.9%).
By immunohistochemistry, the mononuclear cells accu-
mulating in the glomeruli were examined. Macrophages
identified as ED-1–positive cells were the most predom-
inant infiltrates in the glomeruli at day 7 as indicated in
Figures 5 and 6. The macrophage accumulation was re-
markably suppressed by the transfer of Ad-rIL-10 (3 ×
1010 pfu) gene but not by the Ad-LacZ gene. The sup-
pression was confirmed by the reduction of number of
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Fig. 3. Detection of serum interleukin-10 (IL-10) protein level. The
serum IL-10 protein concentration (pg/mL) was measured at day 7
by using enzyme-linked immunosorbent assay (ELISA) technique as
mentioned in the Methods section. Data are expressed as the mean val-
ues ± SD (N = 5) and significance is analyzed by Mann-Whitney test.
∗P < 0.001.
ED-1–positive cells in the glomerular cross-section from
35.7 ± 6.3 cells/gcs (a-GBM antibody alone) to 17.9 ±
5.5 cells/gcs (a-GBM antibody plus Ad-rIL-10, P <0.001).
No significant reduction was observed in a-GBM anti-
body plus Ad-LacZ group, 37.6 ± 8.6 cells/gcs.
Ad-rIL-10 treatment also attenuated the expression
of MHC class II molecules in the glomerular-infiltrated
macrophages (Fig. 5). The numbers of MHC class II
(OX6)–expressing cells in the glomerulus were 14.4 ±
5.3 cells/gcs in the a-GBM antibody–treated animals and
15 ± 4.6 cells/gcs in the a-GBM antibody plus Ad-LacZ–
treated animals. The Ad-rIL-10 gene transfer reduced the
number to 5.7 ± 2.3 cells/gcs significantly (P < 0.0001)
(Fig. 6).
A certain number of CD8+ T cells (5.9 ± 1.5 cells/gcs)
were observed in the glomerulus of the a-GBM antibody–
injected group (Fig. 5). Interestingly, no effect on the
glomerular accumulation of these T cells was observed
in the a-GBM antibody plus Ad-rIL-10–treated animals
(5.4 ± 1.1 OX8+ cells/gcs, P = NS) as in the a-GBM anti-
body plus Ad-LacZ–treated animals (5.8 ± 1.1 cells/gcs,
P = NS) (Fig. 6).
Expression of IL-1b mRNA in glomeruli, spleen, and
lymph nodes. Although IL-1b mRNA was not ex-
pressed in glomeruli, spleen, and lymph nodes ob-
tained from normal control rats, the expression of IL-1b
mRNA was markedly stimulated in the tissues of a-GBM
glomerulonephritis–induced rats at day 7 (Fig. 7). The
treatment with Ad-rIL-10 but not Ad-LacZ suppressed
this expression greatly.
Effect on urinary protein excretion. A single in-
travenous injection of a-GBM antibody increased the
amount of protein excreted in the urine from 2.0 ±
0.7 mg/24 hours before the injection to 20.1 ± 4.4 mg/
24 hours at day 4 and 159.0 ± 22.7 mg/24 hours at day 7
(Fig. 8). The urinary protein excretion was significantly
reduced by the Ad-rIL-10 gene transfer (4.0 ± 1.8 mg/
24 hours at day 3, P < 0.001; and 42.7 ± 35.2 mg/24 hours
at day 7, P < 0.001). No reduction was achieved by the
Ad-LacZ treatment (19.7 ± 2.7 mg/24 hours at day 3 and
166.0 ± 28.0 mg/24 hours at day 7).
Effect on serum creatinine and BUN levels. As shown
in Figure 9, the transfer of IL-10 gene significantly re-
duced the serum creatinine level from 2.8 ± 0.1 mg/dL
(a-GBM antibody alone) or 2.8 ± 0.1 mg/dL (a-GBM an-
tibody + Ad-LacZ) to 1.0 ± 0.1 mg/dL (P < 0.001) and
the BUN concentration from 63.2 ± 8.9 mg/dL (a-GBM
antibody alone) or 61.3 ± 5.2 mg/dL (a-GBM antibody +
Ad-LacZ) to 27.0 ± 4.5 mg/dL (P < 0.001). The serum
concentrations of creatinine and BUN in normal animals
were 0.54 ± 0.1 and 20.0 ± 1.9 mg/dL, respectively.
DISCUSSION
a-GBM crescentic glomerulonephritis is a renal disease
to progress rapidly to deterioration of the renal func-
tion and a poor prognosis in both human and animals.
Since a pivotal role of T-helper 1 immune response in
the glomerular injury has been proposed in experimental
models [8–10], several attempts have been tried to ex-
amine effects of suppression of T-helper 1 response or
enhancement of T-helper 2 response on the development
of the diseases by administrating IL-10 recombinant pro-
tein [9, 19, 20]. However, the results of these studies are
somewhat controversial. A part of the reason may be due
to the inconsistency of IL-10 supply by the intravenous in-
jection of recombinant protein. Gene transfer may over-
come this limitation and supply the translates with more
consistency, although it is still in its infant stage [21, 22].
This study was performed to investigate and explore the
effect of transfer of IL-10 gene encoded in Ad-rIL-10
on the development of crescentic glomerulonephritis in-
duced by a-GBM antibody administration in WKY rats.
First, we examined sites, levels, and time course of Ad-
rIL-10 gene expression when the gene was transferred
intravenously in rats by both RT-PCR and ribonuclease
protection assay. A strong expression for the exogenous
IL-10 mRNA was detected in the liver and its level was
depend on the dose of Ad-rIL-10 injected. The expression
was intense in the liver at days 4 and 7 but was less intense
at day 14. Therefore, the effect of the IL-10 gene over-
expression on the a-GBM crescentic glomerulonephri-
tis was examined by day 7. Consequently, this study
clearly demonstrated that the transfer of Ad-rIL-10 gene
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Fig. 4. Effect of adenoviral vector encoding rat interleukin-10 (Ad-rIL-10) gene transfer on histology of anti-glomerular basement membrane
(a-GBM) disease. (A) A normal control rat kidney. The glomerular hypercellularity with massive accumulation of mononuclear cells and crescent
formation induced at day 7 after a-GBM antibody injection (B) is greatly suppressed by the Ad-rIL-10 (3 × 1010 pfu/rat) gene transfer (C). The
Ad-LacZ-treatment (3 × 1010 pfu/rat) has no suppressive effect on the glomerular histology (D) (original magnification, ×200).
Fig. 5. Effect of adenoviral vector encoding rat interleukin-10 (Ad-rIL-10) gene transfer on glomerular immunohistochemistry. Glomerular accu-
mulation of macrophages is detected by immunohistochemistry using anti-endothelin-1 (ED-1) antibody. Macrophages are scarcely detected in a
glomerulus of normal control rat kidney (A) and are numerous at day 7 of anti-glomerular basement membrane (a-GBM) glomerulonephritis (B).
The number of glomerular macrophages is reduced by the Ad-rIL-10 (3 × 1010 pfu/rat) gene transfer (C) but not by Ad-LacZ administration (D).
Abundant major histocompatibility complex (MHC) class II–expressing cells are immunodetected by OX6 antibody in a glomerulus 7 days after
a-GBM antibody injection (E). The number of MHC class II–expressing cells in a glomerulus is apparently reduced by the Ad-rIL-10 (3 × 1010
pfu/rat) gene transfer (F). Glomerular infiltration with CD8+ T lymphocytes (OX8+) in a-GBM antibody–injected animals is not different between
animals treated (G) and not treated (H) with the Ad-rIL-10 (3 × 1010 pfu/rat) gene transfer (original magnification, ×200).
increased the serum IL-10 level and suppressed this
model significantly as judged by reduction of the
glomerular hypercellularity, glomerular accumulation of
macrophages, and MHC class II–bearing cells, IL-1b
mRNA expression, crescent formation, and proteinuria.
The beneficial effect of IL-10 gene transfer on progres-
sion of the disease was also certified by reduction of serum
creatinine and BUN levels. The results demonstrate that
enhanced IL-10 expression is therapeutic for this model
and probably for human a-GBM disease.
There is now a compelling evidence for the crucial
pathogenic role macrophages in the development and
progression of a-GBM disease [6, 7, 37]. Macrophages
accumulating to the glomerulus were demonstrated to
express MHC class II molecules intensely in a-GBM
glomerulonephritis [30, 31]. It has also been reported
that IL-10 cytokine attenuates activities of macrophages
to express MHC class II molecules for antigen presenta-
tion to T-helper 1 cells [32–35]. In concordance with these
studies, our present study showed an intensive accumula-
tion of macrophages into glomeruli of rats injected with
a-GBM antibody alone or plus Ad-LacZ at day 7. Ad-
ditionally, several MHC class II–positive cells were de-
tected in their glomeruli. By contrast, treatment of the
a-GBM antibody–administrated rats with the Ad-rIL-
10 gene transfer produced a significant reduction in the
numbers of the glomerular macrophages and MHC class
II–positive cells. This effect was dose-dependent of Ad-
rIL-10 gene given to the animals in our separate study
(data not shown) and was accompanied by amelioration
of glomerular hypercellularity and crescent formation,
and proteinuria.
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Fig. 6. Quantitative analysis of the frequency
of crescentic glomeruli and the numbers
of glomerular infiltrates. The percentage of
crescent glomeruli (A) is significantly re-
duced by the adenoviral vector encoding
rat interleukin-10 (Ad-rIL-10) (3 × 1010
pfu/rat) gene transfer. The numbers of antirat
endothelin-1 (ED-1)–positive macrophages
(B), antirat OX6-positive major histocom-
patibility complex (MHC) class II–expressing
cells (C), and antirat OX8-positive CD8 T
cells (D) are counted on 50 glomerular cross-
section (gcs) of each kidney. Gene transfer
with Ad-rIL-10 (3 × 1010 pfu/rat) shows a
significant inhibitory effect on the glomerular
crescent formation and on the glomerular ac-
cumulation with either macrophages or MHC
class II positive cells but not on glomerular in-
filtration with CD8+ cells. Data are expressed
as the mean values ± SD (N = 5), and sig-
nificance is analyzed by Mann-Whitney test
and P value < 0.05 is considered to be signifi-
cant. a-GBM Ab is anti-glomerular basement
membrane antibody.
Many studies have shown a close association between
glomerular accumulation of macrophages and the de-
gree of glomerular injury in experimental glomerular
disease models and a series of macrophage depletion
studies have indicated that the glomerular macrophages
play an essential role in the glomerular injury [36–40].
Moreover, a more recent study carried out by Ikezumi
et al [41] demonstrated that an adoptive transfer of
macrophages after almost complete depletion of leuko-
cytes could solely induce renal injury, glomerular hy-
percellularity and proteinuria in a model of rat a-GBM
glomerulonephritis. Based on this evidence, we may at-
tribute the effects of IL-10 gene transfer on the suppres-
sion of the glomerular injury and crescent formation as
well as urinary protein excretion primarily to the reduc-
tion of the glomerular macrophage accumulation and ac-
tivation by the enhanced IL-10 expression in the present
study.
As well known to our knowledge, the activated
macrophages secrete many cytotoxic molecules and in-
flammatory cytokines, including IL-1b . In addition, it has
been reported that this expression of IL-1b can be used
as an index for macrophage activation [42] and the secre-
tion of IL-1b is considered as an important inducer for
chemokines for macrophages [43]. Furthermore, IL-1b
blocking by administration of IL-1ra, a specific receptor
antagonist for IL-1b , in an experimental model of a-GBM
glomerulonephritis has been shown to cause a marked
reduction of both glomerular macrophage accumulation
and glomerular damage [44]. Our present study showed
a marked expression of IL-1b mRNA in the glomeruli
as well as spleen and lymph nodes at day 7 after the a-
GBM antibody injection. This increase of IL-1b mRNA
expression was markedly suppressed by transfection of
the IL-10 gene.
The crucial pathogenic role of CD8+ T lymphocytes
in the development and progression of human and rat
a-GBM glomerulonephritis now is supported by many
studies [2–6]. Moreover, their depletion by anti-CD8
monoclonal antibody administration was greatly effec-
tive for suppression of experimental models of the dis-
ease [2–5, 45]. However, since glomerular accumulation
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Fig. 7. Effect of adenoviral vector encoding
rat interleukin-10 (Ad-rIL-10) gene transfer
on the expression of IL-1b mRNA in the
glomeruli and immune tissues. IL-1b mRNA
is not expressed in glomeruli, spleen and
lymph nodes of normal control rats (A) lane
1 and (B) lanes 1 and 5, respectively, but is
highly expressed in these tissues after 7 days
of injection with anti-glomerular basement
membrane (a-GBM) antibody (A) lane 2 and
(B) lanes 2 and 6, respectively, or a-GBM
antibody + Ad-LacZ (3 × 1010 pfu/rat) (A)
lane 3 and (B) lanes 3 and 7, respectively. The
treatment with Ad-rIL-10 (3 × 1010 pfu/rat)
greatly reduced the IL-1b mRNA expression
in the glomeruli (A) lane 4, spleen (B) lane
4, and lymph nodes (B) lane 8 of animals
injected with a-GBM antibody. GAPDH is
glyceraldehyde-3-phosphate dehydrogenase.
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Fig. 8. Effect of adenoviral vector encoding rat interleukin-10 (Ad-
rIL-10) gene transfer on urinary protein excretion. Urinary protein ex-
cretion in normal control rats and those injected with anti-glomerular
basement membrane antibody (a-GBM Ab) alone, a-GBM antibody +
Ad-LacZ (3 × 1010 pfu/rat), or a-GBM antibody + Ad-rIL-10 (3 × 1010
pfu/rat) (mean ± SD, N = 5). Statistical significance was analyzed by
Mann-Whitney test and P value < 0.05 is considered to be significant.
of macrophages was also suppressed by the CD8+ T
lymphocyte depletion, it has not been clarified whether
CD8+ T lymphocytes or macrophages accumulated by
CD8+ T lymphocytes injure the glomerular architecture
directly or indirectly. The present study showed that
IL-10 gene transfer has no significant inhibitory effect
on the glomerular accumulation with CD8+ cells. The
result may indicate that macrophages are at least parts
of major players to injure the glomerulus. On the other
hand, it may also indicate that CD8+ T lymphocytes in-
jure the glomerulus directly as well as macrophages since
the glomerular injury was not completely suppressed
by the marked reduction of glomerular macrophage
accumulation.
The present study clearly showed that Ad-rIL-10 in-
jected via tail vein was predominantly overexpressed in
the liver but the expression was negligible in the kidney.
One question may be raised how the overexpressed ex-
ogenous IL-10 gene in extrarenal tissues (e.g., liver) can
affect the events in the kidney and ameliorate its disease.
IL-10 molcules are probably produced in the liver and
delivered to the kidney and immune organs through the
circulation. In the glomerulus, IL-10 may encounter to
its receptor-bearing cells, macrophages and T-helper 1,
which have been accumulated and may change their bi-
ologic activities. The T-helper 1–type immune response
has been suggested to play a great role in the pathogen-
esis and progression of a-GBM glomerulonephritis [10,
36, 46]. Therefore, suppression of the T-helper 1–type im-
mune response may be therapeutic for the disease. Some
of T-helper 2–type cytokine(s) such as IL-10 and IL-4
have been demonstrated to suppress T-helper 1–type im-
mune response [9, 12, 14]. IL-10 administration has been
shown to suppress T-helper 1–type immune response and
to attenuate T-helper 1–type cytokine production [IL-2,
tumor necrosis factor-a (TNF-a), interferon-c (IFN-c)],
antigen-presenting cell function and chemokine receptor
expression in macrophages and T-helper 1 cells [35, 47–
50]. These results stimulate to administer these cytokines
to suppress the a-GBM glomerulonephritis development
and to attenuate its progression [9]. The present study
showed significant suppression of the disease by Ad-rIL-
10 gene transfer, however, how the translated IL-10 sup-
pressed the disease is unclear. As we showed previously
[5], the glomerular expression of IL-2, IFN-c, and TNF-a
(T-helper 1–type cytokines) was very low in this a-GBM
glomerulonephritis model. The result may suggest that
the over-expressed IL-10 may react to macrophages to
suppress their functions but not to T-helper 1 to decrease
T-helper 1–type cytokine production in the glomerulus.
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Fig. 9. Effect of adenoviral vector encoding
rat interleukin-10 (Ad-rIL-10) gene transfer
on serum creatinine and blood urea nitro-
gen (BUN) concentrations. Serum creatinine
and BUN concentrations were measured at
day 7 of normal control rats (lane 1) and
those injected with anti-glomerular basement
membrane (a-GBM) antibody alone (lane 2),
a-GBM antibody + Ad-LacZ (3 × 1010
pfu/rat) (lane 3), or a-GBM antibody + Ad-
rIL-10 (3 × 1010 pfu/rat) (lane 4) (mean ± SD,
N = 5). Statistical significance was analyzed by
Mann-Whitney test. ∗P < 0.05; ∗∗P < 0.01.
On the other hand, IL-10 may react to target cells in im-
mune organs and attenuate systemic immune response,
resulting in the suppression of the glomerulonephritis.
Taken together, IL-10 gene overexpressed in the liver and
released in the circulation may regulate macrophage ac-
tivities and immune responses, which in turn affect the de-
velopment of a-GBM glomerulonephritis either directly
or indirectly in their kidneys.
CONCLUSION
These results demonstrate that IL-10 gene therapy ef-
fectively prevents the development of a-GBM crescentic
glomerulonephritis in WKY rats, and IL-10 gene transfer
may be of use for the treatment of other renal immune
disorders and renal failure.
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